Abstract
Phospho-MurNAc-pentapeptide translocase (MraY, translocase I) catalyses the first step of the lipid-linked cycle of reactions of bacterial peptidoglycan biosynthesis. MraY is the target for five families of nucleoside antibacterial natural products: the tunicamycins, the mureidomycins (also pacidamycins, napsamycins), the liposidomycins, the muraymycins, and the capuramycins. Recent structure-activity studies on these families have led to the identification of active pharmacophores, and insight into their mechanisms of action. This step of peptidoglycan biosynthesis is also the target for the bacteriolytic E protein from bacteriophage φX174, and for cyclic peptides of the amphomycin family which complex the undecaprenyl phosphate co-substrate. The mechanisms of enzyme inhibition by these agents are discussed, and the state of knowledge regarding the transmembrane structure, active site, and catalytic mechanism of MraY. The availability of high throughput assays and prospects of MraY as an antibacterial target are also discussed.
Keywords: Peptidoglycan biosynthesis, antibacterial agents, MraY, high-throughput screening
Infectious Disorders - Drug Targets
Title: Phospho-MurNAc-Pentapeptide Translocase (MraY) as a Target for Antibacterial Agents and Antibacterial Proteins
Volume: 6 Issue: 2
Author(s): Timothy D.H. Bugg, Adrian J. Lloyd and David I. Roper
Affiliation:
Keywords: Peptidoglycan biosynthesis, antibacterial agents, MraY, high-throughput screening
Abstract: Phospho-MurNAc-pentapeptide translocase (MraY, translocase I) catalyses the first step of the lipid-linked cycle of reactions of bacterial peptidoglycan biosynthesis. MraY is the target for five families of nucleoside antibacterial natural products: the tunicamycins, the mureidomycins (also pacidamycins, napsamycins), the liposidomycins, the muraymycins, and the capuramycins. Recent structure-activity studies on these families have led to the identification of active pharmacophores, and insight into their mechanisms of action. This step of peptidoglycan biosynthesis is also the target for the bacteriolytic E protein from bacteriophage φX174, and for cyclic peptides of the amphomycin family which complex the undecaprenyl phosphate co-substrate. The mechanisms of enzyme inhibition by these agents are discussed, and the state of knowledge regarding the transmembrane structure, active site, and catalytic mechanism of MraY. The availability of high throughput assays and prospects of MraY as an antibacterial target are also discussed.
Export Options
About this article
Cite this article as:
Bugg D.H. Timothy, Lloyd J. Adrian and Roper I. David, Phospho-MurNAc-Pentapeptide Translocase (MraY) as a Target for Antibacterial Agents and Antibacterial Proteins, Infectious Disorders - Drug Targets 2006; 6 (2) . https://dx.doi.org/10.2174/187152606784112128
DOI https://dx.doi.org/10.2174/187152606784112128 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Editorial (Asia-Pacific Health 2020 and Genomics without Borders: Co-Production of Knowledge by Science and Society Partnership for Global Personalized Medicine)
Current Pharmacogenomics and Personalized Medicine Immunomodulatory Activity of Garlic
Current Immunology Reviews (Discontinued) DNA Vaccination in Oncology: Current Status, Opportunities and Perspectives
Current Clinical Pharmacology Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry Quinoxaline 1,4-di-N-Oxide and the Potential for Treating Tuberculosis
Infectious Disorders - Drug Targets Preventive Strategies for Ventilator Associated Pneumonia
Current Respiratory Medicine Reviews New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Current Pharmaceutical Design Advances in the Synthesis of Calystegines and Related Products and their Biochemical Properties
Mini-Reviews in Medicinal Chemistry Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Multi-Target Drugs for Neglected Diseases
Current Pharmaceutical Design Serum and Bronchoalveolar Lavage Fluid 25(OH)Vitamin D3 Levels in HIV-1 and Tuberculosis: A Cross-Sectional Study from a Tertiary Care Center in North India
Current HIV Research Biomarkers of Asthma: Recent Patents from 2009-2011
Recent Patents on Biomarkers Regulation of Cytokine Production by γδ T Cells
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Structural Bioinformatic Approaches to the Discovery of New Antimycobacterial Drugs
Current Pharmaceutical Design HIF-1α Deficiency Perturbs T and B Cell Functions
Current Pharmaceutical Design Visceral Leishmaniasis: Advances in Treatment
Recent Patents on Anti-Infective Drug Discovery The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain
Current Neuropharmacology